Moderna leads structurally, with growth as the clearest single gap between the two profiles. Roivant Sciences still has the edge on stability, which keeps the comparison from looking entirely one-sided. The market setup is broadly comparable for both — no clear directional signal from price behavior. The market is not adding a decisive signal either way — the structural read carries the weight.
The comparison is based on similar long-term financial trajectories, not sector labels. Both peer scores are relative to the Russell 1000 universe, making them directly comparable.
The comparison is mainly decided in growth, with the rest of the profile carrying less weight. The overall score gap is 10 points in favour of Moderna, Inc..
Both operate in: Biotechnology
This comparison is based on industry proximity, not on functional trajectory similarity. MRNA and ROIV share the same industry classification.
For a similarity-based comparison, see how Moderna and Roivant Sciences each position within their functional peer groups in AssetNext.
Scores reflect position relative to comparable companies with similar long-term financial trajectories.
Score differences across key dimensions.
Left means cheaper relative valuation. Higher means stronger structure.
The setup stays mixed because structure and the price setup do not align cleanly in one direction.
Valuation position uses peer-relative valuation score where available.
Where MRNA and ROIV each sit in their own 5-year price and valuation history.
Describes historical entry positioning only. Descriptive — not investment advice.
One company is still expanding while the other is contracting, which creates a very wide growth split.
Roivant Sciences Ltd. still carries lower volatility exposure — that difference is real enough to prevent the comparison from becoming one-sided.
The growth lead is clear, but pricing and stability still pull in the other direction — the result holds, but not without friction.
Break down the MRNA vs ROIV comparison across all dimensions with the full interactive tool.
Explore how MRNA and ROIV each compare against other companies in their peer groups.
Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.
AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.
Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.
Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.
Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.